Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 51299 | 3.695 |
09:34 ET | 2850 | 3.69 |
09:36 ET | 9084 | 3.695 |
09:38 ET | 25235 | 3.675 |
09:39 ET | 5429 | 3.675 |
09:41 ET | 17572 | 3.675 |
09:43 ET | 6304 | 3.68 |
09:45 ET | 10619 | 3.675 |
09:48 ET | 4178 | 3.685 |
09:50 ET | 1650 | 3.68 |
09:52 ET | 26911 | 3.695 |
09:54 ET | 4504 | 3.695 |
09:56 ET | 3090 | 3.685 |
09:57 ET | 9214 | 3.68 |
09:59 ET | 4050 | 3.675 |
10:01 ET | 74903 | 3.665 |
10:03 ET | 2887 | 3.665 |
10:06 ET | 2450 | 3.66 |
10:08 ET | 5563 | 3.665 |
10:10 ET | 43915 | 3.675 |
10:12 ET | 26982 | 3.675 |
10:14 ET | 58613 | 3.68 |
10:15 ET | 9149 | 3.6899 |
10:17 ET | 16309 | 3.6799 |
10:19 ET | 31672 | 3.675 |
10:21 ET | 10057 | 3.685 |
10:24 ET | 5802 | 3.685 |
10:26 ET | 10883 | 3.675 |
10:28 ET | 26400 | 3.695 |
10:30 ET | 7065 | 3.69 |
10:32 ET | 14239 | 3.6949 |
10:33 ET | 14673 | 3.685 |
10:35 ET | 7248 | 3.695 |
10:37 ET | 11161 | 3.705 |
10:39 ET | 2800 | 3.705 |
10:42 ET | 20027 | 3.715 |
10:44 ET | 14662 | 3.705 |
10:46 ET | 7796 | 3.705 |
10:48 ET | 3150 | 3.705 |
10:50 ET | 129924 | 3.705 |
10:51 ET | 51797 | 3.695 |
10:53 ET | 28109 | 3.685 |
10:55 ET | 4145 | 3.685 |
10:57 ET | 4881 | 3.685 |
11:00 ET | 7758 | 3.685 |
11:02 ET | 12990 | 3.675 |
11:04 ET | 7040 | 3.66 |
11:06 ET | 7044 | 3.665 |
11:08 ET | 48907 | 3.665 |
11:09 ET | 5050 | 3.665 |
11:11 ET | 8151 | 3.655 |
11:13 ET | 10769 | 3.65 |
11:15 ET | 55513 | 3.645 |
11:18 ET | 25676 | 3.645 |
11:20 ET | 12801 | 3.645 |
11:22 ET | 11947 | 3.655 |
11:24 ET | 3888 | 3.655 |
11:26 ET | 12801 | 3.645 |
11:27 ET | 38543 | 3.635 |
11:29 ET | 5100 | 3.63 |
11:31 ET | 18563 | 3.633 |
11:33 ET | 29919 | 3.635 |
11:36 ET | 8536 | 3.6319 |
11:38 ET | 62768 | 3.645 |
11:40 ET | 15351 | 3.635 |
11:42 ET | 9477 | 3.63 |
11:44 ET | 8483 | 3.635 |
11:45 ET | 18550 | 3.635 |
11:47 ET | 16843 | 3.635 |
11:49 ET | 16613 | 3.64 |
11:51 ET | 17610 | 3.645 |
11:54 ET | 4146 | 3.64 |
11:56 ET | 6916 | 3.645 |
11:58 ET | 12033 | 3.645 |
12:00 ET | 3037 | 3.645 |
12:02 ET | 14465 | 3.645 |
12:03 ET | 25394 | 3.645 |
12:05 ET | 6887 | 3.65 |
12:07 ET | 5987 | 3.64 |
12:09 ET | 53638 | 3.645 |
12:12 ET | 7096 | 3.645 |
12:14 ET | 6210 | 3.64 |
12:16 ET | 3919 | 3.64 |
12:18 ET | 2900 | 3.65 |
12:20 ET | 38870 | 3.635 |
12:21 ET | 6542 | 3.635 |
12:23 ET | 10219 | 3.635 |
12:25 ET | 4910 | 3.64 |
12:27 ET | 2498 | 3.635 |
12:30 ET | 3184 | 3.635 |
12:32 ET | 3184 | 3.635 |
12:34 ET | 2313 | 3.64 |
12:36 ET | 3783 | 3.63 |
12:38 ET | 4762 | 3.63 |
12:39 ET | 4345 | 3.6369 |
12:41 ET | 52924 | 3.63 |
12:43 ET | 10294 | 3.63 |
12:45 ET | 3847 | 3.635 |
12:48 ET | 6902 | 3.635 |
12:50 ET | 15190 | 3.625 |
12:52 ET | 3416 | 3.62 |
12:54 ET | 4276 | 3.63 |
12:56 ET | 169727 | 3.63 |
12:57 ET | 4670 | 3.63 |
12:59 ET | 14050 | 3.63 |
01:01 ET | 19175 | 3.635 |
01:03 ET | 4787 | 3.64 |
01:06 ET | 5871 | 3.6367 |
01:08 ET | 2185 | 3.635 |
01:10 ET | 7880 | 3.635 |
01:12 ET | 12454 | 3.64 |
01:14 ET | 3761 | 3.64 |
01:15 ET | 96702 | 3.645 |
01:17 ET | 6704 | 3.645 |
01:19 ET | 831 | 3.6462 |
01:21 ET | 6000 | 3.645 |
01:24 ET | 3805 | 3.64 |
01:26 ET | 6114 | 3.645 |
01:28 ET | 1048 | 3.645 |
01:30 ET | 2858 | 3.645 |
01:32 ET | 3805 | 3.645 |
01:33 ET | 5418 | 3.64 |
01:35 ET | 9213 | 3.645 |
01:37 ET | 36931 | 3.635 |
01:39 ET | 400 | 3.63 |
01:42 ET | 5230 | 3.63 |
01:44 ET | 2251 | 3.635 |
01:46 ET | 4468 | 3.635 |
01:48 ET | 3012 | 3.635 |
01:50 ET | 3069 | 3.63 |
01:51 ET | 900 | 3.635 |
01:53 ET | 2275 | 3.635 |
01:55 ET | 2525 | 3.64 |
01:57 ET | 16468 | 3.635 |
02:00 ET | 7249 | 3.635 |
02:02 ET | 272925 | 3.635 |
02:04 ET | 116728 | 3.645 |
02:06 ET | 16911 | 3.66 |
02:08 ET | 2876 | 3.65 |
02:09 ET | 3400 | 3.65 |
02:11 ET | 4610 | 3.66 |
02:13 ET | 5923 | 3.655 |
02:15 ET | 1462 | 3.655 |
02:18 ET | 47641 | 3.64 |
02:20 ET | 3400 | 3.645 |
02:22 ET | 17755 | 3.63 |
02:24 ET | 1622 | 3.63 |
02:26 ET | 3941 | 3.635 |
02:27 ET | 20088 | 3.63 |
02:29 ET | 35542 | 3.625 |
02:31 ET | 65405 | 3.63 |
02:33 ET | 5112 | 3.635 |
02:36 ET | 3400 | 3.63 |
02:38 ET | 34940 | 3.625 |
02:40 ET | 17042 | 3.625 |
02:42 ET | 1000 | 3.625 |
02:44 ET | 6073 | 3.625 |
02:45 ET | 26185 | 3.62 |
02:47 ET | 369560 | 3.626 |
02:49 ET | 33225 | 3.635 |
02:51 ET | 26800 | 3.635 |
02:54 ET | 75469 | 3.64 |
02:56 ET | 96245 | 3.645 |
02:58 ET | 3583 | 3.645 |
03:00 ET | 14198 | 3.645 |
03:02 ET | 14047 | 3.66 |
03:03 ET | 3987 | 3.66 |
03:05 ET | 74660 | 3.67 |
03:07 ET | 12687 | 3.68 |
03:09 ET | 15899 | 3.69 |
03:12 ET | 5692 | 3.69 |
03:14 ET | 4766 | 3.685 |
03:16 ET | 5043 | 3.685 |
03:18 ET | 8486 | 3.685 |
03:20 ET | 67111 | 3.675 |
03:21 ET | 12465 | 3.675 |
03:23 ET | 5140 | 3.675 |
03:25 ET | 116235 | 3.665 |
03:27 ET | 1851 | 3.66 |
03:30 ET | 5193 | 3.665 |
03:32 ET | 1000 | 3.665 |
03:34 ET | 41341 | 3.675 |
03:36 ET | 3514 | 3.68 |
03:38 ET | 19618 | 3.675 |
03:39 ET | 4015 | 3.68 |
03:41 ET | 24168 | 3.67 |
03:43 ET | 58444 | 3.665 |
03:45 ET | 49843 | 3.655 |
03:48 ET | 13863 | 3.66 |
03:50 ET | 12611 | 3.655 |
03:52 ET | 176601 | 3.66 |
03:54 ET | 79371 | 3.655 |
03:56 ET | 174074 | 3.66 |
03:57 ET | 114805 | 3.665 |
03:59 ET | 159341 | 3.66 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.2B | -10.6x | --- |
Vera Therapeutics Inc | 2.1B | -18.6x | --- |
CG Oncology Inc | 2.1B | -27.3x | --- |
Rocket Pharmaceuticals Inc | 2.0B | -7.8x | --- |
Janux Therapeutics Inc | 2.4B | -37.0x | --- |
Keros Therapeutics Inc | 1.8B | -9.9x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -10.6x |
Price/Sales (TTM) | 4,174.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.